Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.74 +3.3%	$4.83	$2.90 ▼ $11.16	$293.61M	-0.01	3.02 million shs	3.95 million shs
CADL Candel Therapeutics	$6.40 +0.8%	$5.82	$3.79 ▼ $14.60	$318.15M	-0.88	742,183 shs	860,459 shs
JMAC Maxpro Capital Acquisition	$5.69 +0.3%	$6.16	$7.50 ▼ $19.22	$145.16M	0.01	74,040 shs	54,241 shs
LFCR Lifecore Biomedical	$7.74 +1.4%	$7.50	$3.68 ▼ $8.85	$285.42M	0.65	123,592 shs	179,239 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+7.10%	-1.36%	-12.56%	-36.49%	-41.80%
CADL Candel Therapeutics	+2.25%	+2.92%	+9.29%	+18.91%	+13.80%
JMAC Maxpro Capital Acquisition	+0.26%	-3.07%	+4.40%	+9.42%	+3,436.36%
LFCR Lifecore Biomedical	+5.68%	+5.24%	-8.07%	+14.39%	+40.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.1848 of 5 stars	4.3	3.0	0.0	0.0	1.8	1.7	0.6
CADL Candel Therapeutics	2.3526 of 5 stars	3.6	2.0	0.0	0.0	1.9	1.7	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	0.6823 of 5 stars	1.3	0.0	0.0	0.0	1.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	365.24% Upside
CADL Candel Therapeutics	3.20	Buy	$22.00	243.75% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	3.36% Upside

Current Analyst Ratings Breakdown

Latest JMAC, CADL, ALT, and LFCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
8/13/2025	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	15,167.57	N/A	N/A	$1.74 per share	2.15
CADL Candel Therapeutics	$120K	2,672.00	N/A	N/A	$1.41 per share	4.54
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	$128.87M	2.25	N/A	N/A	$0.37 per share	20.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-65.97%	-59.23%	N/A
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)

Latest JMAC, CADL, ALT, and LFCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	N/A	N/A	N/A	$35.36 million	N/A
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
CADL Candel Therapeutics	0.01	4.64	4.64
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
LFCR Lifecore Biomedical	113.76	2.84	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CADL Candel Therapeutics	13.93%
JMAC Maxpro Capital Acquisition	73.18%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
CADL Candel Therapeutics	16.60%
JMAC Maxpro Capital Acquisition	19.27%
LFCR Lifecore Biomedical	32.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable

JMAC, CADL, ALT, and LFCR Headlines

Recent News About These Companies

Craig-Hallum Sticks to Its Buy Rating for Lifecore Biomedical (LFCR)

August 12 at 2:22 AM | theglobeandmail.com

Lifecore Biomedical Full Year 2025 Earnings: EPS Beats Expectations

August 11 at 8:21 PM | finance.yahoo.com

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

August 7, 2025 | globenewswire.com

DCF Advisers LLC Sells 56,989 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

August 4, 2025 | marketbeat.com

Lifecore Biomedical, Inc. to Report Q4 and Fiscal Year 2025 Financial Results on August 7, 2025

July 31, 2025 | quiverquant.comQ

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025

July 31, 2025 | globenewswire.com

Laughing Water Capital’s View on Lifecore Biomedical (LFCR)

July 24, 2025 | finance.yahoo.com

Laughing Water Capital’s View on Lifecore Biomedical Inc. (LFCR)

July 24, 2025 | insidermonkey.com

Lifecore Biomedical (NASDAQ:LFCR) Trading Down 2.5% - What's Next?

July 19, 2025 | marketbeat.com

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2025 | globenewswire.com

Lifecore Biomedical Insider Ups Holding During Year

July 7, 2025 | finance.yahoo.com

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy

June 18, 2025 | kalkinemedia.comK

Lifecore Biomedical: Inflecting Financials Over Next 3 Years

June 18, 2025 | seekingalpha.com

Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement

June 17, 2025 | msn.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.comA

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17, 2025 | globenewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 15, 2025 | accessnewswire.comA

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale

June 14, 2025 | nasdaq.com

Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | finanznachrichten.de

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

June 12, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JMAC, CADL, ALT, and LFCR Company Descriptions

Altimmune NASDAQ:ALT

$3.74 +0.12 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.76 +0.02 (+0.53%)

As of 07:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Candel Therapeutics NASDAQ:CADL

$6.40 +0.05 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 -0.02 (-0.31%)

As of 06:55 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Maxpro Capital Acquisition NASDAQ:JMAC

$5.69 +0.02 (+0.26%)

As of 08/11/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Lifecore Biomedical NASDAQ:LFCR

$7.74 +0.11 (+1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$7.74 0.00 (0.00%)

As of 05:38 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time